Coya Therapeutics, Inc. (COYA) AI Stock Analysis

• Market Cap: N/A
• Dividend Yield: N/A
• Average Volume (3M): 50.35K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.23
• Revenue Growth: -40.79%
• EPS Growth: -16.57%
• Country: US
• Employees: 8
• Sector: Healthcare
• Sector Strength: 39
• Industry: Biotechnology
• EPS (TTM): -0.44
• Shares Outstanding: 16,724,998
• 10 Day Avg. Volume: 62,867
• 30 Day Avg. Volume: 50,354
• PEG Ratio: 0.00
• Price to Book (P/B): 5.33
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -113.06
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: 1.35
• Enterprise Value/Gross Profit: 9.66
• Enterprise Value/Ebitda: -0.61
• 1Y Price Target: $16.75
• Price Target Upside: 185.35% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4

• Rating: 48 Neutral
• Price Target: ―

Coya Therapeutics, Inc. has a mixed outlook. Strong clinical progress and financial stability from a debt-free balance sheet with cash reserves are significant positives. However, persistent profitability and cash flow challenges weigh heavily on the overall score. Technical indicators suggest moderate momentum, while valuation remains pressured by ongoing losses. The company's strategic advancements and funding efforts are positive but need to translate into improved financial performance to enhance the stock's appeal.

Positive Factors

Drug Development Progress

The IND resubmission potentially allows the Phase 2/3 trial to begin soon, indicating progress in the company's drug development.

Financial Support

Coya would be eligible to receive milestone payments totaling $8.4M from strategic partner, Dr. Reddy’s Laboratories, upon IND acceptance and first patient dosing of COYA-302 in ALS.

Investor Interest

The potential impact of the COYA-303 program, which uses a combination of low dose IL2 and a GLP-1 receptor agonist, could draw investor interest due to its promise in treating AD patients.

Negative Factors

Clinical and Regulatory Risks

Risks include, but are not limited to: clinical setbacks involving COYA 302 in ALS and/or AD; inability to advance into pivotal development with COYA 302; failure to secure U.S. regulatory approval of COYA 302.

Regulatory Approval Challenges

Failure to secure U.S. regulatory approval of COYA 302 remains a risk factor for the company.

Coya Therapeutics, Inc. Business Overview & Revenue Model

Company Description

Coya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a Treg-enhancing biologic for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous and/or intravenous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an allogeneic Treg exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company was incorporated in 2020 and is headquartered in Houston, Texas.

How the Company Makes Money

Coya Therapeutics, Inc. generates revenue through the development and commercialization of its proprietary therapies. The company primarily earns money by advancing its drug candidates through clinical trials, seeking regulatory approval, and ultimately bringing successful treatments to market. Revenue streams may include product sales, licensing agreements, and strategic partnerships with other biotechnology and pharmaceutical companies. These partnerships often involve collaborative research and development efforts, as well as milestone and royalty payments based on the successful commercialization of joint projects. Additionally, Coya may receive funding from grants or government programs aimed at supporting innovative medical research.

Coya Therapeutics, Inc. Financial Statement Overview

Summary

Coya Therapeutics, Inc. shows strong revenue growth and a debt-free balance sheet with ample cash reserves. However, significant profitability issues due to high operating losses and negative cash flows overshadow these positives. The financial health is stable but requires strategic improvements in cost management.

Income Statement

Coya Therapeutics, Inc. has shown a massive increase in revenue in 2024, but the profitability remains a significant concern with negative EBIT and net income. The company has a gross profit margin of 100% due to revenue matching gross profit, but high operating losses lead to negative EBIT and net profit margins. The revenue growth from 2023 to 2024 is impressive but overshadowed by substantial net losses, suggesting the company struggles with profitability in scaling.

Balance Sheet

The balance sheet shows a strong equity position with no debt, resulting in a zero debt-to-equity ratio, which is favorable. The equity ratio is high, and the company has ample cash reserves relative to liabilities. However, the high net losses impact return on equity negatively. Overall, the balance sheet reflects financial stability with a robust cash position but is challenged by poor profitability metrics.

Cash Flow

Coya Therapeutics, Inc. has negative operating and free cash flows, indicating cash outflows surpass inflows from operations. There is no free cash flow growth, and both operating and free cash flows to net income ratios are negative, highlighting cash management challenges. Despite significant financing cash inflows, the cash flow situation remains strained due to continuous operational losses.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	3.68M	3.55M	6.00M	0.00	0.00	0.00
Gross Profit	3.68M	3.55M	6.00M	-27.36K	-16.13K	0.00
EBITDA	-19.41M	-17.22M	-7.88M	-12.22M	-4.85M	10.44K
Net Income	-17.14M	-14.88M	-7.99M	-12.24M	-4.89M	-733.00K
Balance Sheet
Total Assets	38.40B	44.35M	41.26M	8.40M	4.79M	8.75M
Cash, Cash Equivalents and Short-Term Investments	35.53B	38.34B	32.63M	5.93M	4.34M	8.72M
Total Debt	0.00	0.00	0.00	12.97M	0.00	0.00
Total Liabilities	5.04B	4.77M	5.63M	16.79M	1.15M	447.12K
Stockholders Equity	33.37B	39.58B	35.64M	-8.39M	3.64M	8.30M
Cash Flow
Free Cash Flow	-2.84B	-10.29M	-11.19M	-7.24M	-4.04M	-391.27K
Operating Cash Flow	-2.84B	-10.29M	-11.19M	-7.24M	-3.90M	-391.27K
Investing Cash Flow	-24.98M	-25.00K	-543.19K	-525.00K	-136.80K	0.00
Financing Cash Flow	33.92M	16.03M	38.43M	9.36M	-340.58K	9.11M

Coya Therapeutics, Inc. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 5.87
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For COYA, the sentiment is Positive. The current price of 5.87 is above the 20-day moving average (MA) of 5.71, above the 50-day MA of 5.83, and below the 200-day MA of 6.30, indicating a neutral trend. The MACD of 0.04 indicates Negative momentum. The RSI at 57.14 is Neutral, neither overbought nor oversold. The STOCH value of 51.41 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for COYA.

Coya Therapeutics, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	52 Neutral	$7.45B	0.27	-61.87%	2.30%	16.62%	1.04%
COYA	48 Neutral		―	-52.00%	―	-40.79%	-16.57%
BOLT	45 Neutral	$11.25M	―	-83.92%	―	-67.87%	0.40%
GRI	45 Neutral	$3.45M	―	-468.00%	―	―	98.55%
SNSE	40 Underperform	$11.53M	―	-64.18%	―	―	1.00%
INAB	34 Underperform	$7.23M	―	-174.66%	―	―	38.53%
GLTO	29 Underperform	$4.30M	―	-91.32%	―	―	48.81%

Coya Therapeutics, Inc. Corporate Events

Coya Therapeutics Reports 2024 Financial Results and Updates

Coya Therapeutics, Inc. provided a corporate update and reported its financial results for the fiscal year 2024, highlighting significant advancements in its clinical trials and financial positioning. The company announced positive outcomes from various studies, including improvements in inflammatory markers in Alzheimer’s patients and progress in trials for Frontotemporal Dementia and Amyotrophic Lateral Sclerosis. Financially, Coya raised $10 million through a private placement and received strategic investments to support its pipeline development. Despite a net loss increase to $14.9 million in 2024, the company remains optimistic about its future milestones and the potential of its therapeutic approaches to create shareholder value.